DiabetesPhase 1NCT02449187
Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers
A Phase 1 study testing JLP-1310, Fasted followed by fed and JLP-1310, Fed followed by fasted in people with Diabetes and Hyperlipidemia, run by Jeil Pharmaceutical Co., Ltd. at 1 site in South Korea.
Trial summary
A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers. Read more about this study
- Who is it for?
- Ages 19 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Diabetes, Hyperlipidemia
- What is being tested?
- JLP-1310, Fasted followed by fed and JLP-1310, Fed followed by fasted
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteSouth Korea
- Study dates
- 2 Aug 2017to 9 Mar 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy male volunteer, age is over 19 years
- Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2
- Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
- Subject who has the ability and willingness to participate the whole period of trial
Who cannot join
- Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
- Subjects who are allergic to investigational drug.
- Subjects who have a medical history which can affect the clinical trial.
- Hypertension(Systolic BP ≥ 140mmHG or Diastolic BP ≥ 90mmHg), Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a half times.
- History of drug abuse or positive drug screening.
- Participation in other drug studies within 3 months prior to the drug administration.
- Whole blood donation within 60 days, blood component donation within 30 days or who got transfusion within 30days.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers
A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers.
Read the detailed description
A randomized, open-label, single dose, crossover clinical trial.
- Conditions
- Diabetes, Hyperlipidemia
- Being tested
- JLP-1310, Fasted followed by fed, JLP-1310, Fed followed by fasted
- Medical subject headings
- Diabetes Mellitus, Hyperlipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JLP-1310, Fasted followed by fedDrug
Also called metformin hydrochloride, rosuvastatin calcium
In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition.
JLP-1310, Fed followed by fastedDrug
Also called metformin hydrochloride, rosuvastatin calcium
In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition.
| Study group | Role | What they receive |
|---|---|---|
| JLP-1310, Fasted followed by fed | Experimental | JLP-1310 dosing in the fasted state followed by fed dosing
Interventions:
Drug: JLP-1310 Receives: Drug: JLP-1310, Fasted followed by fed |
| JLP-1310, Fed followed by fasted | Experimental | JLP-1310 dosing in the fasted state followed by fed dosing
Interventions:
Drug: JLP-1310 Receives: Drug: JLP-1310, Fed followed by fasted |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax
Measured: 48 hours from baseline
AUC(last)
Measured: 48 hours from baseline
Secondary outcomes (5)
AUC(inf)
Measured: 48 hours from baseline
Tmax
Measured: 48 hours from baseline
T1/2
Measured: 48 hours from baseline
CL/F
Measured: 48 hours from baseline
Vd/F
Measured: 48 hours from baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2015 (estimated)
- Study start2 Aug 2017
- Primary completion15 Sep 2017
- Study completion9 Mar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Sang Heon Cho, MD., Ph.D, Principal investigator, Inha University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02449187
- Sponsor's protocol ID
- JLP-1310-102-FE
- Status last verified
- Mar 2018
- First submitted
- 13 May 2015
- Last updated
- 29 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers
- ClinicalTrials.gov ID
- NCT02449187
- Acronym / sponsor ID
- JLP-1310-102-FE
- Conditions
- Diabetes, Hyperlipidemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 2 Aug 2017 (actual)
- Primary completion
- 15 Sep 2017 (actual)
- Study completion
- 9 Mar 2018 (actual)
- First posted
- 20 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, open-label, single dose, crossover study to investigate the effect of food on the pharmacokinetics of JLP-1310 in healthy male volunteers.
Detailed description
A randomized, open-label, single dose, crossover clinical trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| JLP-1310, Fasted followed by fed | Experimental | Drug: JLP-1310, Fasted followed by fedJLP-1310 dosing in the fasted state followed by fed dosing Interventions: Drug: JLP-1310 |
| JLP-1310, Fed followed by fasted | Experimental | Drug: JLP-1310, Fed followed by fastedJLP-1310 dosing in the fasted state followed by fed dosing Interventions: Drug: JLP-1310 |
Who may qualify
- Ages
- 19 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy male volunteer, age is over 19 years
- Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2
- Subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial
- Subject who has the ability and willingness to participate the whole period of trial
Key exclusion criteria (7 listed)
- Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system.
- Subjects who are allergic to investigational drug.
- Subjects who have a medical history which can affect the clinical trial.
- Hypertension(Systolic BP ≥ 140mmHG or Diastolic BP ≥ 90mmHg), Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a half times.
- History of drug abuse or positive drug screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JLP-1310, Fasted followed by fedAlso: metformin hydrochloride, rosuvastatin calciumIn period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition. In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition. | Drug | JLP-1310, Fasted followed by fed |
| JLP-1310, Fed followed by fastedAlso: metformin hydrochloride, rosuvastatin calciumIn period 1, the subjects will receive an oral pill of JLP-1310 under fed condition. In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition. | Drug | JLP-1310, Fed followed by fasted |
Primary outcome
Cmax
Time frame: 48 hours from baseline
AUC(last)
Time frame: 48 hours from baseline
5 secondary outcomes
AUC(inf)
Time frame: 48 hours from baseline
Tmax
Time frame: 48 hours from baseline
T1/2
Time frame: 48 hours from baseline
CL/F
Time frame: 48 hours from baseline
Vd/F
Time frame: 48 hours from baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2018.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sang Heon Cho, MD., Ph.D principal investigator
Inha University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing JLP-1310, Fasted followed by fed and JLP-1310, Fed followed by fasted in people with Diabetes and Hyperlipidemia, run by Jeil Pharmaceutical Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax (time frame: 48 hours from baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2018.